In contrast, in bladder cancer, high SEPHS1 expression is associated with increased tumor mutational burden, elevated PD-L1 expression, and improved immunotherapy response, possibly due to enhanced neoantigen release. The gene discussed is SEPHS1; the disease is urinary bladder cancer.